tradmap

DFTX Definium Therapeutics, Inc.

$33.41 +2.93%

Data as of close

Healthcare · Medicinal Chemicals & Botanical Products

Definium Therapeutics, Inc. (DFTX) is a healthcare company in the Medicinal Chemicals & Botanical Products industry, with a market capitalization of $4.5 billion. Shares last traded at $33.41.

Market Cap
$4.5B
Shares Out
134.4M
EPS (TTM)
-$3.36
P/E (TTM)*
—
P/S Ratio
—
P/B Ratio
4.89
Dividend / Share
—
Dividend Yield
—
52-Week High
—
52-Week Low
—
Volume (venue)
110,317
Avg Vol (3m, venue)
125,994.937

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
-9.89%
1M
-7.83%
3M
-24.79%
6M
+49.09%
YTD
+117.02%
1Y
—

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
41.19
SMA (50)
$37.31
SMA (200)
$29.78
Price vs SMA50
-10.45%
Price vs SMA200
+12.19%
ATR (14)
$2.03

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
—
Net Income
-$354M
Gross Margin
—
Operating Margin
—
Net Margin
—
Return on Equity
-38.5%
Return on Assets
-31.8%
Current Ratio
6.95
Debt / Equity
0.04
Revenue Growth (YoY)
—

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 -$1.44 2026-08-06
Q1 2026 -$0.71 2026-05-07
Q4 2025 (derived) -$0.43 2026-02-26
FY 2025 -$2.06 2026-02-26
Q3 2025 -$0.78 2025-11-06
Q2 2025 -$0.50 2025-07-31

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Medicinal Chemicals & Botanical Products peers

DFTX vs 14 industry peers (Medicinal Chemicals & Botanical Products), by market cap. Data as of close

1–14 of 14
DFTXDefinium Therapeutics, Inc.$4.5B———+2.93%
RGCRegencell Bioscience Holdings Ltd$3.0B———-2.55%
TRLVTrulieve Cannabis Corp.$2.2B—1.95-41.8%+3.78%
CRONCronos Group$1.2B17.826.9639.1%+1.04%
TLRYTilray Brands$393M—0.41-17.1%+4.72%
SNDLSNDL Inc.$354M———+5.08%
CGCCanopy Growth$301M—1.43-80.0%+4.42%
ACBAurora Cannabis$290M———+22.16%
USNAUSANA HEALTH SCIENCES INC$275M—0.30-2.4%+1.16%
GLASGlass House Brands Inc.$190M—1.04-16.3%-0.85%
NAGENiagen Bioscience, Inc.$187M11.681.4512.4%-1.67%
MDWDMediWound Ltd.$173M———-0.52%
FTLFFITLIFE BRANDS, INC.$76M12.190.756.2%-2.06%
BTMDbiote Corp.$32M5.530.183.2%-0.44%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.